Article Text

Download PDFPDF
Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis
  1. Ladislav Šenolt1,
  2. Markéta Polanská1,
  3. Maria Filková1,
  4. Lucie Andrés Cerezo1,
  5. Karel Pavelka1,
  6. Steffen Gay2,
  7. Martin Haluzík3,
  8. Jiří Vencovský1
  1. 1Institute of Rheumatology, Connective Tissue Research Laboratory, Prague, Czech Republic
  2. 2Center of Experimental Rheumatology, University Hospital Zurich, Switzerland
  3. 33rd Medical Department – Clinical Department of Endocrinology and Metabolism of the First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
  1. Correspondence to Dr Ladislav Šenolt, Institute of Rheumatology, Na Slupi 4, 12850 Prague 2, Czech Republic; seno{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Scientific interest in adipose tissue-derived peptides has increased dramatically in recent years.1 Several mediators known as adipo(cyto)kines were first associated with the pathophysiology of obesity-related complications; however, a significant role for adipokines such as leptin, adiponectin, resistin and visfatin in regulating immune responses and inflammation has recently been discovered.1 2 Several reports3,,6 have already demonstrated association of these adipokines with the severity of rheumatoid arthritis (RA).

Vaspin, a member of the serine protease inhibitor family, and omentin (also known as intelectin) were recently identified in adipose tissue.7 8 Vaspin is an adipokine with insulin-sensitising effects that has been suggested to be a compensatory mediator for abrogating obesity and its inflammatory complications.7 Expression of the omentin gene was demonstrated in omental adipose tissue of patients …

View Full Text


  • Patient consent Obtained.

  • Competing Interests None.

  • Ethics approval This study was conducted with the approval of the local ethics committee and all patients gave informed consent.

  • Provenance and peer review Not commissioned; externally peer reviewed.